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Dr. Borgelt will be discussing unapproved drugs and uses.
Dr. Borgelt has served as a member of six working groups:
§ Colorado Department of Public Health and Environment (CDPHE): 
Amendment 64 (Marijuana Legalization) Task Force Working Group: 
Consumer Safety and Social Issues
§ State Licensing Authority Labeling, Packaging, Product Safety and 
Marketing
§ State Licensing Authority Medical and Retail Marijuana Mandatory 
Testing and Random Sampling 
§ State Licensing Authority Serving Size and Product Potency 
§ CDPHE Retail Marijuana Public Health Advisory Committee
§ CDPHE Pregnancy and Breastfeeding Guidelines Committee
Objectives
§ Describe the pharmacology of cannabis.
§ Evaluate and discuss clinical studies using medical cannabis 
that have been performed in patients with neuropathic pain.
§ Compare and contrast clinical studies that have evaluated 
medical cannabis use in patients with pediatric epilepsy and 
other neurologic disorders.
§ Review clinical studies that have evaluated medical cannabis 
use in patients with gastrointestinal disorders.
Audience Question
1. Yes, medical purposes only
2. No, recreational purposes only
3. Yes, both
4. No
I know someone who consumes 




2. improve symptoms of nausea and vomiting
3. relieve muscle spasms associated with multiple sclerosis
4. get high
I believe the most common reason 
people seek out marijuana is to... 
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Marijuana
§ Single molecule pharmaceuticals
§ Dronabinol (Schedule III) 
§ Nabilone (Schedule II)
§ Liquid extract: nabiximols (Sativex®)
§ Approved in 27 countries; U.S. - Phase III trials
§ Liquid extract: cannabidiol (Epidiolex®)
§ FDA: orphan drug status for Dravet and Lennox-Gastaut syndromes
§ Expanded access INDs to several independent investigators
§ Phytocannabinoid-dense botanicals
§ Cannabis sativa – medicinal plant (Schedule I)
Cannabis
§ Plant-derived cannabinoids
§ ∆9 -tetrahydrocannabinol - THC
§ ∆8 -tetrahydrocannabinol - THC
§ Cannabidiol – CBD
§ Cannabinol - CBN
§ Cannabigerol - CBG
§ Cannabichromene - CBC
§ Cannabicyclol - CBL
§ Cannabielsoin - CBE





§ And much more…
Br J Pharmacology 2006;147:S163-71 Br J Pharmacology 2011;163:1344-64
1. Cannabinoid-1 receptor (CB1)
2. Cannabinoid-7 receptor (CB7)
3. Peroxisome Proliferator-Activated Receptors (PPAR) 
4. G-protein receptor 55 (GPR55)
5. I have no idea J
Which of the following receptors is a 
key target for THC?
Audience Question
Endogenous Cannabinoid System
§ Endocannabinoids and their receptors found throughout body: brain, organs, 
connective tissues, glands, and immune cells. 
§ In each tissue, the cannabinoid system performs different tasks; goal is 
always homeostasis
§ When cannabinoid receptors are stimulated, a variety of physiologic 
processes occur
§ CB1 receptors: nervous system, connective tissues, gonads, glands, organs
§ CB2 receptors: immune system and associated structures




http://norml.org/library/item/introduction-to-the-endocannabinoid-system Accessed June 9, 2015
Neuro Endocrinol Lett. 2008 Apr;29(2):192-200.
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Structure Anandamide regulates Resultant effect
Spinal cord Inhibit GLU & info transfer between body & brain Decreased pain sensitivity
Parasympathetic 
system
Inhibit Ach release, HR regulation, urination regulation HR stimulation, sometimes inhibits urination
Sympathetic system Inhibit NE release, HR regulation, blood vessel constriction Delayed reduction in HR and blood pressure
Neuronal cells Inhibition GLU-induced excitotoxicity Neuroprotective effect to prevent cell injury
Adipose tissue Stimulates lipogenesis Increased adiposity, insulin resistance
Reproductive tissue Reduces testosterone, luteinizing hormone Reduced fertility, altered menstrual cycle
Skin Reduces histamine Anti-pruritic effect
General Role in relaxing, eating, sleeping, forgetting protecting Provide relief from stress, reduction of injury
General Inhibits immune B lymphocytes, natural killer cells Anti-inflammatory activity
http://headsup.scholastic.com/students/more-facts-about-how-drug-abuse-puts-your-whole-body-at-risk
Functional Effects of Anandamide 
at CB1 & CB2 Receptors
14
What happens when 







Pertwee RG. Br J Pharmacology 2008;153:199-215. 
Smith SC. Neuro Endocrinol Lett. 2014;35(3):198-201.
Endogenous Cannabinoid System 





Non-Cannabinoid Targets Linked to Cannabis
§ Other G-protein receptors:  GPR55, GPR55940, etc.
§ G-protein-coupled receptors:  noncompetitive inhibitor at μ- and d-opioid 
receptors, NE, DA, 5-HT
§ Ligand-gated ion channels:  allosteric antagonism at 5-HT3, nicotinic, 
and enhance activation of glycine receptors
§ Transient receptor potential channels (TRPVs):  bind and activate 
TRPV1 similar to capsaicin, also CB1 receptors are located near TRPV1
§ Ion channels:  inhibition of Ca, K, Na channels by non-competitive 
antagonism
§ Peroxisome Proliferator-Activated Receptors:  PPARa and PPARg are 
activated 
N Engl J Med 2015;373:1048-58. Bioorg Med Chem 2015;23:1377-85.
Another Kid on the Block…Cannabidiol (CBD)
Epilepsia 2014;55(6):791–802. http://www.projectcbd.org/news/how-cbd-works/ Accessed 06/13/16
Little binding affinity to CB1/CB2
Suppresses enzyme fatty acid 
amide hydroxylase (“FAAH”) –














Structure THC effect CBD effect
Neocortex Altered thinking, judgement Delayed onset time to intoxication with THC
Basal ganglia Slowed reaction time Reduced psychomotor abnormalities from THC
Hypothalamus ↑ appetite No to little effect on appetite
Amygdala Panic, paranoia Decrease THC induced anxiety
Nucleus accumbens Euphoria Attenuated THC induced euphoria
Hippocampus Impaired memory Attenuated THC induced memory effects
Cerebellum Impaired coordination Reduced coordination abnormalities from THC
Brain stem Anti-nausea effects
Hippocampus, forebrain Anti-epileptic effects ? Anti-epileptic effects for certain populations


























Considerations for medical use of marijuana are different 
than considerations for recreational use of marijuana.
Medical use: benefit – risk
Recreational use: risk - risk
Summary: Endocannabinoid System and THC
Reprinted with permission. Nat Rev Gastroenterol Hepatol. 2014;11(3):142-3
THC
Objectives
§ Describe the pharmacology of cannabis.
§ Evaluate and discuss clinical studies using medical cannabis 
that have been performed in patients with neuropathic pain.
§ Compare and contrast clinical studies that have evaluated 
medical cannabis use in patients with pediatric epilepsy and 
other neurologic disorders.
§ Review clinical studies that have evaluated medical cannabis 
use in patients with gastrointestinal disorders.
Patient Experience with MMJ
§ VIDEO: Teri Robnett
https://www.youtube.com/watch?v=eyw1utFTaug
A. Blog






H. Randomized controlled 
trial
I. Review article
“LOWEST” level of evidence
“HIGHEST” level of evidence
How Should MMJ Be Studied?
Cannabinoids for Medical Use: 
Systematic Review and Meta-Analysis










Chronic pain 8 Reduction of 30% or more in pain




Spasticity related to 
MS or paraplegia
8 Ashworth spasticity scale




*Variety of cannabinoid products evaluated
**WMD: weighted mean difference
**Common AEs of cannabinoids included dizziness, dry mouth, nausea, fatigue, somnolence, euphoria, vomiting, disorientation, 
drowsiness, confusion, loss of balance, and hallucination.
Inhaled Cannabis for Neuropathic Pain: 
Meta-Analysis of Individual Data
§ Synthesizes the individual participants' original data obtained from the studies' 
principal investigators
§ Five randomized controlled trials evaluating inhaled cannabis
§ Compared proportion of patients experiencing >30% clinical improvement in 
chronic neuropathic pain assessed with a continuous patient-reported 
instrument (e.g., visual analog scale) at baseline and after inhaled cannabis
RESULTS
• 178 patients with 405 observed responses
• Estimated OR (CRI) for >30% ↓ in pain score: 3.22 (1.59-7.24)
• Number needed to treat (CRI): 5.55 (3.35-13.7)
Note: gabapentin NNT 5.9 (4.6-8.3) for diabetic neuropathy
J Pain 2015;16:1221-32. Cochrane Database of Systematic Reviews 2014, Issue 4. 
Art. No.: CD007938. 
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Adverse Effects
§ Serious Adverse Effects (SAEs)
» Placebo: 1 (psychosis)
» Cannabis: 2 (hypertension, increased pain)
§ Mild adverse effects
» Anxiety, disorientation, difficulty concentrating, headache, dry 
eyes, burning sensation, dizziness, and numbness
» Psychoactive effects (such as feeling “high”) were statistically 
significantly associated with treatment allocation in 2 studies and 
increased in frequency with increasing dose
J Pain. 2015 Dec;16(12):1221-32. doi: 10.1016/j.jpain.2015.07.009. Epub 2015 Sep 9. 
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Limitations and Conclusions
§ Ineffective participant blinding
§ Placebo effects likely
§ Different causes of neuropathy
§ Small number of studies and participants
§ Difficult to estimate bioavailable cannabis
§ Short-term data only (up to two weeks)
Inhaled cannabis results in short-term 
reductions in chronic neuropathic pain for 1 
in every 5 to 6 patients treated.
J Pain. 2015 Dec;16(12):1221-32. doi: 10.1016/j.jpain.2015.07.009. Epub 2015 Sep 9.
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Crossover Study: Low-dose Vaporized Cannabis
§ Objective: evaluate analgesic 
efficacy in patients with 
neuropathic pain despite 
traditional treatments
§ Visual analog scale (0-100)
§ 39 patients with previous 
cannabis exposure
» 28 male/11 female


















P vs Low: p=0.0069
P vs Med: p=0.0023




J Pain. 2013 Feb;14(2):136-48. doi: 10.1016/j.jpain.2012.10.009.
Smoked Cannabis for Chronic Neuropathic Pain
§ 21 adults post-traumatic or 
post-surgical neuropathic 
pain
§ Cannabis 25 mg at 0%, 
2.5%, 6%, and 9.4% THC 
smoked 3x/day
§ Four 14-day periods in 
crossover trial




§ Pain intensity 
Ø 9.4%: score = 5.4
Ø 0%: score = 6.1
Ø (p=0.023; difference 0.7, 95% CI 0.02-
1.4)
§ Sleep (more drowsiness, getting to sleep 
more easily, faster, and with less 
wakefulness)
Ø 9.4% vs 0%: p<0.05
§ Anxiety and depression improved (EQ5D)
Ø 9.4% vs 0%: p<0.05
§ Adverse events
Ø 248 mild; 6 moderate (fall, ↑pain, 
numbness, drowsiness, pneumonia)
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CMAJ. 2010 Oct 5;182(14):E694-701. doi: 10.1503/cmaj.091414
MMJ in Painful HIV-Associated Sensory Neuropathy: 
Systematic Review and Meta-Analysis
§ Objective: evaluate 
clinical effectiveness of 
various analgesics
§ Total of 14 trials 
evaluated
§ Smoked cannabis 1-8% 
and capsaicin 8% found 
to be effective
PLoS ONE [Electronic Resource]. 5(12):e14433, 2010
SMOKED CANNABIS
Number of episodes 122
≥30% improvement in VAS 31/61
≥50% improvement in VAS 15/61
RR (95% CI) 2.38 (1.38 to 4.10)
NNT (95% CI) 3.38 (2.19 to 7.50)
*NNT for capsaicin 8% = 6.46 (3.86-19.69)
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Medical Cannabis and Opioid Use
34
From: Medical Cannabis Laws and Opioid Analgesic Overdose Mortality in the United States, 1999-2010
JAMA Intern Med. 2014;174(10):1668-1673. doi:10.1001/jamainternmed.2014.4005
States with medical cannabis laws had a 24.8% lower 
mean annual opioid overdose mortality rate 
(95% CI,−37.5% to −9.5%; P = .003) 
compared with states without medical cannabis laws. 
This association strengthened over time
Year 1 (−19.9%; 95% CI,−30.6% to -7.7%; P = .002) 
Year 2 (−25.2%; 95% CI,−40.6% to −5.9%; P = .01) 
Year 3 (−23.6%; 95% CI,−41.1% to −1.0%; P = .04) 
Year 4 (−20.2%; 95% CI,−33.6% to −4.0%; P = .02) 
Year 5 (−33.7%; 95% CI,−50.9% to -10.4%; P = .008) 
Year 6 (−33.3%; 95% CI,−44.7% to -19.6%; P < .001)
Medical Cannabis and Opioid Use
§ 244 medical cannabis patients with chronic pain in Michigan
§ Survey of 46 questions
» Medical condition(s) for which cannabis was used
» Method/frequency of cannabis use
» Changes in noncannabis medication use
» Changes in medication side effects
» Quality of life changes since starting cannabis use
» Demographic information
» 2011 Fibromyalgia Survey Criteria (0-31 score)
J Pain. 2016 Jun;17(6):739-44. doi: 10.1016/j.jpain.2016.03.002. Epub 2016 Mar 19.
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OUTCOME OF INTEREST PATIENT RESPONSES 
(n=244)
Mean (SD)
Fibromyalgia score (0-31) 9.23 (5.52)
Opioid use change −63% (46%)
Degree to which side effects of medication affect daily 
function (before using medical cannabis); scale from 1 to 
10
6.44 (2.91)
Degree to which side effects of medication affect daily 
function (after using medical cannabis); scale from 1 to 10
2.77 (2.35)
Number of medication classes used (before cannabis use) 2.35 (1.43)
Number of medication classes used (after cannabis use) 1.82 (.94)
Quality of life change 45% (28%)
J Pain. 2016 Jun;17(6):739-44. doi: 10.1016/j.jpain.2016.03.002. Epub 2016 Mar 19.
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Summary
Cannabis may have a role in chronic pain, especially 
neuropathic pain when patients have failed other treatments. 
Mortality from and use of opioids appears to decrease with 
cannabis use. Adverse effects do occur so benefits and risks 
should be weighed for individual patients while considering 
patient safety and public health concerns.
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Objectives
§ Describe the pharmacology of cannabis.
§ Evaluate and discuss clinical studies using medical cannabis 
that have been performed in patients with neuropathic pain.
§ Compare and contrast clinical studies that have evaluated 
medical cannabis use in patients with pediatric epilepsy and 
other neurologic disorders.
§ Review clinical studies that have evaluated medical cannabis 
use in patients with gastrointestinal disorders.
Pediatric Epilepsy: AES Annual Meeting 2015
§ 261 children (average age 11 years)
§ Severe epilepsy not responding to other treatments
§ Epidiolex given in increasing doses with other AEDs (avg=3)
§ After 3 months of treatment
» 45% lower frequency of seizures
» 47% experienced ≥50% reduction in seizures
» 9% seizure-free
» Dravet syndrome patients: 62% reduction in seizures, 13% seizure free
» Lennox-Gastaut patients: 71% reduction in atonic seizures
§ Adverse effects (>10%)
» Sleepiness, diarrhea, fatigue (4% discontinued treatment)
§ Serious adverse effects: 5% treatment-related
» Altered liver enzymes, status epilepticus, diarrhea and others
§ Lack of efficacy caused 12% withdrawal
http://www.medicalnewstoday.com/articles/303725.php Accessed 6/13/16
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Pediatric Epilepsy: Israeli Experience
§ Retrospective review of 74 patients (1-18 years) with 
intractable epilepsy using CBD-enriched medical cannabis
§ Resistant to >7 antiepileptic drugs
§ Treated with CBD-enriched product for at least 3 months
» CBD:THC – 20:1 
» CBD dose ranged from 1-20 mg/kg/day
§ Seizure frequency assessed by parental report





















<10 mg/kg/d >10 mg/kg/d
Seizure Reduction with Cannabis Use
0% reduction <25% reduction 25-50% reduction 50-75% reduction >75% reduction Total
Seizure. 2016 Feb;35:41-4. doi: 10.1016/j.seizure.2016.01.004. Epub 2016 Jan 6.
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Adverse Effects
§ Reported in 34/74 patients
» Seizure aggravation: 13 (18%)
» Somnolence/fatigue: 16 (22%)
» Gastrointestinal problems and irritability: 5 (7%)
Note: side effects led to withdrawal in 5 patients
Seizure. 2016 Feb;35:41-4. doi: 10.1016/j.seizure.2016.01.004. Epub 2016 Jan 6.
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Limitations and Conclusions
§ Lack of a control group
§ No consistent rate of dosage elevation
§ Reliance upon parental report on seizure frequency
§ Short duration of the study
§ Lack of long-term outcome
§ No EEG results and no measurement of other drug levels
Results of this multicenter study on CBD treatment for intractable epilepsy 
in a population of children and adolescents are highly promising
Seizure. 2016 Feb;35:41-4. doi: 10.1016/j.seizure.2016.01.004. Epub 2016 Jan 6.
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Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Report of the Guideline Development Subcommittee of the American Academy of Neurology
Neurology. 2014;82(17):1556-63
Condition Effective Possibly effective Probably or possibly ineffective
Spasticity OCE Nabiximols, THC
Central pain or painful 
spasms
OCE Nabiximols, THC
Urinary dysfunction Nabiximols THC, OCE
Tremor THC, OCE, nabiximols
In Patients with Multiple Sclerosis
*OCE= oral cannabis extract
“The risks and benefits of medical marijuana should be weighed carefully.”
“Comparative effectiveness of medical marijuana vs other therapies is 
unknown for these indications.”
Nabiximols (Sativex®)
» Spasticity (muscle 
stiffness/spasm) due to MS
» Neuropathic pain in MS
» Adjunctive analgesic treatment 
in patients with advanced cancer 
who experience moderate to 
severe pain during the highest 
tolerated dose of strong opioid 







Indications for Whole Plant Extracts
Objectives
§ Describe the pharmacology of cannabis.
§ Evaluate and discuss clinical studies using medical cannabis 
that have been performed in patients with neuropathic pain.
§ Compare and contrast clinical studies that have evaluated 
medical cannabis use in patients with pediatric epilepsy and 
other neurologic disorders.
§ Review clinical studies that have evaluated medical cannabis 
use in patients with gastrointestinal disorders.
Irritable Bowel Syndrome & Crohn’s Disease
§ 313 patients with irritable bowel disease surveyed at University of Calgary
§ Comparison of patients that used cannabis and those that did not
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Inflamm Bowel Dis. 2014 Mar;20(3):472-80. doi: 10.1097/01.MIB.0000440982.79036.d6.
• 17.6% of respondents used cannabis to relieve IBD symptoms
• Most chose inhalation route of administration (96.4%)
• Improved symptoms of IBD (next slide)
• Cannabis use >6 months at any time for IBD symptoms was a strong 
predictor of requiring surgery in patients with Crohn's disease (OR = 
5.03, 95% CI = 1.45–17.46) 















Abdominal pain Abdominal cramping Joint pain Diarrhea
Symptom improvement (%)




§ Prospective cohort survey study of 292 patients
Ø Among current and past users (51.3%), 16.4% of patients used marijuana for disease symptoms
• Majority felt marijuana was "very helpful" for relief of abdominal pain, nausea, and diarrhea
§ Observational study of 30 patients with Crohn's disease (CD),
Ø Medical cannabis associated with improvement in disease activity
Ø Reduction in the use of other medications
§ Placebo-controlled study in 21 chronic CD patients
Ø Decrease in CD activity index >100 in 10 of 11 subjects on cannabis compared to 4 of 10 on placebo
Ø Complete remission was achieved in 5 of 11 subjects on cannabis group and 1 of 10 on placebo 
§ Observational study (number of participants not provided)
Ø Low-dose cannabidiol did not have an effect on CD activity.
Dig Dis. 2014;32(4):468-74. doi: 10.1159/000358155. Epub 2014 Jun 23.
Inflamm Bowel Dis. 2013 Dec;19(13):2809-14. doi: 10.1097/01.MIB.0000435851.94391.37
Other Interesting Clinical Findings
§ Migraine
§ Pharmacotherapy. 2016;36(5):505-10
§ Pediatric treatment-resistant epilepsy: parental reports
§ Epilepsy Behav 2015;47:138-41
§ Epilepsy Behav 2015;45:49-52
§ Epilepsy Behav 2013;29:574-7
§ PTSD: cannabis used more frequently for sleep and coping
§ Drug and Alcohol Dependence 2014;136:162–5
§ J Psychoactive Drugs 2014;46:73-7
§ Alzheimer’s Disease
§ Clin Pharmacol Ther. 2015 Jun;97(6):597-606
§ J Neuroimmune Pharmacol. 2015 Jun;10(2):268-80
§ Bladder Cancer
§ Urology. 2015 Feb;85(2):388-92
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Summary
Cannabis may have a role in a variety of conditions when 
patients have failed other FDA-approved treatments. Adverse 
effects do occur so benefits and risks should be weighed for 
individual patients while considering patient safety and public 
health concerns.
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Am J Health-Syst Pharm. 2007; 64:1037-1044. Pharmacotherapy 2013;33:195-209.










- Lethargy, Sedation, Slowed Reaction Time
- Psychological dysfunction: impaired coordination, memory formation, recollection, focus)
- Visual Disturbances 
EUPHORIA
Conclusions
§ Marijuana and its active components impact the endocannabinoid 
system to provide various effects. 
§ Many dosage formulations of marijuana available to patients.
§ Clinical studies performed in children and adults demonstrate 
some effectiveness for certain conditions including neuropathic 
pain, epilepsy, and gastrointestinal conditions. 
§ Adverse effects are reported in all studies so benefits and risks 
must be carefully weighed. 
QUESTIONS?
Laura.Borgelt@ucdenver.edu
